Contemporary Options for the Management of Motor Complications in Parkinson’s Disease: Updated Clinical Review

@article{Cabreira2019ContemporaryOF,
  title={Contemporary Options for the Management of Motor Complications in Parkinson’s Disease: Updated Clinical Review},
  author={Ver{\'o}nica Cabreira and Patr{\'i}cio Soares-da-Silva and Jo{\~a}o Massano},
  journal={Drugs},
  year={2019},
  volume={79},
  pages={593-608}
}
Parkinson’s disease (PD) is a chronic, progressive condition affecting around 1% of the population older than 60 years. Upon long-term treatment with levodopa, the mainstay of treatment in PD, most patients, especially younger ones exposed to higher doses, will experience symptoms related to end-of-dose deterioration, peak-dose dyskinesias, and other motor fluctuations. Therapeutic strategies are grounded on modification of oral levodopa pharmacokinetics to extend levodopa benefit and… 
A Stage-Based Approach to Therapy in Parkinson’s Disease
TLDR
A practical, stage-based guide to pharmacological management of both motor and non-motor symptoms of PD is provided, to help the physician in yielding the best therapeutic strategies for each symptom and condition in patients with PD.
Istradefylline to Treat Patients with Parkinson’s Disease Experiencing “Off” Episodes: A Comprehensive Review
TLDR
Istradefylline, a novel adenosine A2A receptor antagonist, is indicated as a treatment addition to levodopa/carbidopa in patients experiencing “off episodes” of Parkinson’s disease.
Intrajejunal Infusion of Levodopa/Carbidopa for Advanced Parkinson's Disease: A Systematic Review
TLDR
LCIG may be a favorable option for patients with advanced Parkinson's disease who show predominant nonmotor symptoms and vulnerability to complications of other advanced therapy modalities and larger, well‐controlled studies, including precise investigation of cost effectiveness, would further assist treatment selection.
Improvements in clinical signs of Parkinson’s disease using photobiomodulation: a prospective proof-of-concept study
TLDR
Photobiomodulation was shown to be a safe and potentially effective treatment for a range of clinical signs and symptoms of PD and indicates that a large RCT is warranted.
Improvements in the clinical signs of Parkinson's disease using photobiomodulation: a prospective proof of concept study
TLDR
Photobiomodulation was shown to be a safe and potentially effective treatment for a range of clinical signs and symptoms of PD and indicates that a large RCT is warranted.
Opicapone: A Review in Parkinson’s Disease
  • L. Scott
  • Medicine, Psychology
    CNS Drugs
  • 2021
TLDR
Given its efficacy and safety profile, adjunctive opicapone remains an important option in the management of adults with PD and EoD motor fluctuations who cannot be stabilized on preparations of L-dopa/DDCI.
The Comparative Efficacy of Non-ergot Dopamine Agonist and Potential Risk Factors for Motor Complications and Side Effects From NEDA Use in Early Parkinson's Disease: Evidence From Clinical Trials
TLDR
NEDA therapy reduces motor symptoms and improves ADLs in early PD, and the odds of developing motor complications were lower with NEDA than with LD, and dyskinesia increased with increasing LD equivalent dose and was not influenced by N EDA treatment duration.
Levodopa Inhalation Powder: A Review in Parkinson’s Disease
TLDR
Providing a nonintrusive, convenient treatment method, levodopa inhalation powder is a promising option for the intermittent treatment of OFF episodes in patients with Parkinson’s disease treated with a LD-DCI.
The role of selected antioxidants in the development and treatment of Parkinson’s disease
TLDR
It is reasonable to say that antioxidant deficiencies should be avoided and the physiological levels should be sought, as this may be translated into significant health benefits.
Guidelines for Parkinson's disease treatment: consensus from the Movement Disorders Scientific Department of the Brazilian Academy of Neurology - motor symptoms.
TLDR
The main published treatment guidelines for Parkinson's disease were reviewed based on the recommendations of group from the Movement Disorders Scientific Department of the Brazilian Academy of Neurology.
...
...

References

SHOWING 1-10 OF 144 REFERENCES
Medical Management of Levodopa-Associated Motor Complications in Patients with Parkinson’s Disease
TLDR
When choosing a drug to treat levodopa-induced complications, it is important to consider the risks and benefits of the different classes and of the specific agents within each class, given the different efficacy and safety profiles of each.
Medical and surgical management of advanced Parkinson's disease
TLDR
Some of the newer available therapeutic opportunities such as use of enzyme inhibitors like opicapone and safinamide, adenosine A2A receptor antagonists, apomorphine and levodopa/carbidopa intestinal gel infusion, deep brain stimulation including the role of closed‐loop and adaptive stimulation, and MRI‐guided focused ultrasound are summarized.
Therapeutic strategies to prevent and manage dyskinesias in Parkinson’s disease
TLDR
Benefits and limits of available therapeutic approaches aimed at delaying or managing dyskinesias as well as new strategies that are currently under investigation are discussed.
Does levodopa slow or hasten the rate of progression of Parkinson’s disease?
TLDR
The clinical outcomes of the ELLDOPA trial indicate that levodopa is effective in a dose-dependent manner in overcoming the signs and symptoms of PD, and support the concept that the drug does not hasten the disease progression, but rather may slow down the rate of the disease.
Clinical spectrum of levodopa‐induced complications
  • C. Aquino, S. Fox
  • Psychology, Medicine
    Movement disorders : official journal of the Movement Disorder Society
  • 2015
TLDR
Patients develop a range of l‐dopa–induced complications that include motor and non‐motor symptoms, particularly fluctuations in neuropsychiatric, autonomic, and sensory symptoms.
Levodopa and the progression of Parkinson's disease.
TLDR
The clinical data suggest that levodopa either slows the progression of Parkinson's disease or has a prolonged effect on the symptoms of the disease, and the neuroimaging data suggest either thatlevodopa accelerates the loss of nigrostriatal dopamine nerve terminals or that its pharmacologic effects modify the dopamine transporter.
Randomized trial of safinamide add-on to levodopa in Parkinson's disease with motor fluctuations
TLDR
The addition of safinamide 50 mg/day or 100mg/day to l‐dopa in patients with PD and motor fluctuations significantly increased total on time with no or nontroublesome dyskinesia, decreased off time, and improved parkinsonism, indicating thatsafinamide improves motor symptoms and parkinsonistan without worsening dyskineia.
Impact of Functional Age on the Use of Dopamine Agonists in Patients With Parkinson Disease
  • D. Silver
  • Medicine, Psychology
    The neurologist
  • 2006
TLDR
Dopamine agonists are safe and effective in elderly PD patients and offer numerous advantages when used as either monotherapy or adjunctive therapy, particularly in patients requiring long-term treatment.
New treatments for levodopa‐induced motor complications
TLDR
Randomized controlled trials conducted in patients suffering from already established complications showed that new levodopa (l‐dopa) formulations such as intrajejunal l‐dop–carbidopa infusion and bilayered extended‐release l‐Dopa–car bidopa (IPX066) can improve motor fluctuations.
Evaluation of the efficacy of pramipexole for treating levodopa-induced dyskinesia in patients with Parkinson's disease.
TLDR
Pramipexole may be a therapeutic option for treating LID because its effects on D3 dopamine receptors may balance the D1 dopamine receptor supersensitivity associated with LID.
...
...